CLDX
$19.88
Revenue | $1.18Mn |
Net Profits | $-47.09Mn |
Net Profit Margins | -4007.83% |
Celldex Therapeutics, Inc.’s revenue fell -71.56% since last year same period to $1.18Mn in the Q4 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -63.18% fall in its revenue since last 3-months.
Celldex Therapeutics, Inc.’s net profit fell -8.74% since last year same period to $-47.09Mn in the Q4 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -11.8% fall in its net profits since last 3-months.
Celldex Therapeutics, Inc.’s net profit margin fell -282.31% since last year same period to -4007.83% in the Q4 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -203.62% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.69 |
EPS Estimate Current Year | -0.69 |
Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.69 - a 3.44% jump from last quarter’s estimates.
Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.69.
Earning Per Share (EPS) | -0.71 |
Celldex Therapeutics, Inc.’s earning per share (EPS) jumped 14.46% since last year same period to -0.71 in the Q4 2024. This indicates that the Celldex Therapeutics, Inc. has generated 14.46% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2024-05-06 | -0.69 | -0.56 | 18.84% |
2025-02-27 | -0.71 | -0.71 | 0.64% |
2024-11-06 | -0.67 | -0.64 | 4.48% |
2024-08-08 | -0.59 | -0.54 | 8.47% |